<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2020.9.n975</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-975</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group></article-categories><title-group><article-title>C-реактивный белок и его ассоциации с кардиометаболическими факторами риска и эхокардиографическими индикаторами сердечной недостаточности: результаты исследования «Узнай свое сердце» в г. Архангельске</article-title><trans-title-group xml:lang="en"><trans-title>C-reactive protein and its associations with сardiometabolic risk factors and echocardiographic indicators of heart failure: results of “Know your heart” study in Arkhangelsk</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4562-8398</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миролюбова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mirolyubova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н.,профессор, заведующий кафедрой факультетской терапии</p><p>SPIN-код 3916-2492</p></bio><bio xml:lang="en"><p>D.M.S., professor. Cardiologist. Head, Chair of Faculty Therapy of the Northern State Medical University</p></bio><email xlink:type="simple">o.mirolyubova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8902-8947</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудрявцев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudryavtsev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Заведующий отделом инновационных программ центральной научно-исследовательской лаборатории ФГБОУ ВО «Северный государственный медицинский университет»</p><p> </p></bio><bio xml:lang="en"><p>PhD.</p><p>Head, Dept. of Innovative Programs,Central Scientific Research Laboratory</p><p>Ass. Professor, Arctic Health Research,Dept. of Community Medicine,Faculty of Health Sciences,</p></bio><email xlink:type="simple">ispha09@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семчугова</surname><given-names>Э. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Semchyugova</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клинический ординатор 2-го года по специальности кардиология. Соискатель. Утверждена тема кандидатской диссертации.</p></bio><bio xml:lang="en"><p>Clinical ordinator/ Speciality is Cardiology</p></bio><email xlink:type="simple">sannysailor@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6539-0466</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малютина</surname><given-names>С. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Malyutina</surname><given-names>S. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., профессор, заведующий лабораторией этиопатогенеза и клиники внутренних заболеваний</p></bio><bio xml:lang="en"><p>D.M.S., professor</p></bio><email xlink:type="simple">smalyutina@hotmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9868-855X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябиков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabikov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., профессор, заведующий курсом ультразвуковой</p><p>диагностики факультета повышения квалификации и профессиональной</p></bio><bio xml:lang="en"><p>D.M.S., professor</p></bio><email xlink:type="simple">a_ryabikov@hotmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северный государственный медицинский университет» Минздрава РФ, Архангельск, Россия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Northern State Medical University, Arkhangelsk, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт терапии и профилактической медицины – филиал «ИЦиГ» СО РАН, Новосибирск, Россия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Internal and Preventive Medicine, Branch of Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава РФ, Новосибирск, Россия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University, Novosibirsk, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>10</month><year>2020</year></pub-date><volume>60</volume><issue>9</issue><fpage>68</fpage><lpage>75</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/975">https://cardio.elpub.ru/jour/article/view/975</self-uri><abstract><p>Цель Оценка связи высокочувствительного С-реактивного белка (вчСРБ) с кардиометаболическими и эхокардиографическими (ЭхоКГ) индикаторами сердечной недостаточности (СН) среди взрослого населения Северного региона России.Материал и методы Поперечное исследование «Узнай свое сердце» проведено в 2015–2017 гг. на случайной выборке общего населения г. Архангельска в возрасте 35–69 лет (n=2381). Критерием исключения для данного анализа был уровень вчСРБ &gt;10 мг / л. В группу с наличием субклинического воспаления вошло 686 участников с вчСРБ ≥2,0 мг / л, а 1158 участников с вчСРБ &lt;2,0 мг / л составили группу сравнения. В анализ включены кардиометаболические факторы риска, ЭхоКГ показатели систолической и диастолической функции левого желудочка (ЛЖ) и биомаркеры (NT-proBNP, вчТропонин Т, цистатин С). Использовали линейные и логистическую регрессии.Результаты В группе с вчСРБ ≥2,0 мг / л выявлена более высокая частота артериальной гипертензии, сахарного диабета, СН, перенесенного инфаркта миокарда, чем в группе сравнения. Определены независимые ассоциации уровня вчСРБ с окружностью талии (β=0,379, p &lt;0,001), мужским полом (β=–0,135, p&lt;0,001), курением (β=0,109, p&lt;0,001), уровнем триглицеридов (β=0,083, p&lt;0,001), диастолическим артериальным давлением (β=0,082, p&lt;0,001), уровнем цистатина C (β=0,082, p&lt;0,001), гликированного гемоглобина (β=0,064, p=0,003) и липопротеидов низкой плотности (ЛПНП) (β=0,049, p=0,025). В качестве независимых предикторов субклинического воспаления показаны пожилой возраст, курение, абдоминальное ожирение, повышенные значения ЛПНП (&gt;3,0 ммоль / л), триглицеридов (&gt;1,7 ммоль / л) и цистатина С (&gt;1,2 мг / л). Определены независимые отрицательные ассоциации вчСРБ с фракцией выброса ЛЖ, индексом объема левого предсердия, отношением скорости раннего и позднего диастолического наполнения ЛЖ (p=0,003, p=0,002, p=0,005 соответственно), отражающие связь повышенного содержания вчСРБ с ухудшением систолической и диастолической функции ЛЖ. Продемонстрирована связь показателей ремоделирования сердца с уровнем NT-proBNP.Заключение На популяционной выборке взрослого населения Северного региона России выявлены независимые ассоциации вчСРБ с факторами кардиометаболического риска, а также структурными и функциональными изменениями сердца по данным ЭхоКГ, что отражает потенциальное участие воспаления в ремоделировании сердца и развитии СН.</p></abstract><trans-abstract xml:lang="en"><p>Aim To evaluate the relationship between high-sensitivity C-reactive protein (hsCRP) and echocardiographic (EchoCG) indicators of heart failure (HF) among adult population of the North region of Russia.Material and methods The Know Your Heart transversal study was performed in 2015–2017 on a random sample of adult population of Arkhangelsk aged 35–69 years (n=2381). The exclusion criterion for this study was a concentration of hsCRP &gt;10 mg/l. The group of subclinical inflammation included 686 participants with hsCRP ≥2.0 mg/l; the comparison group consisted of 1158 participants with hsCRP &lt;2.0 mg/l. Analysis included cardiometabolic risk factors, EchoCG indexes of left ventricular (LV) systolic and diastolic function and biomarkers (NT-proBNP, hsTroponin Т, cystatin С). Linear and logistic regressions were used.Results The group with hsCRP ≥2.0 mg/l had higher rates of arterial hypertension, diabetes mellitus, HF, and myocardial infarction in history than the comparison group. The hsCRP level was independently associated with waist circumference (β=0.379, p &lt;0.001), male gender (β=–0.135, p&lt;0.001), smoking (β=0.109, p&lt;0.001), triglycerides (β=0.083, p&lt;0.001), diastolic blood pressure (β=0.082, p&lt;0.001), cystatin C (β=0.082, p&lt;0.001), glycated hemoglobin (β=0.064, p=0.003), and low-density lipoproteins (LDL) (β=0.049, p=0.025). Independent predictors of subclinical inflammation included older age, smoking, abdominal obesity, elevated values of LDL (&gt;3.0 mmol/l), triglycerides (&gt;1.7 mmol/l), and cystatin C (&gt;1.2 mg/l). hsCRP was independently negatively associated with LV ejection fraction, left atrial volume index, ratio of early to late LV diastolic filling velocity (p=0.003, p=0.002, p=0.005, respectively), which reflected the relationship of the increased content of hsCRP with impairment of LV systolic and diastolic function. A relationship between heart remodeling indexes and hsCRP concentration was shown.Conclusion In a sample of adult population from the North region of Russia, the hsCRP concentration was independently associated with cardiometabolic risk factors and structural and functional changes in the heart detected by EchoCG, which reflects a potential contribution of inflammation to heart remodeling and development of HF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>С-реактивный белок</kwd><kwd>факторы риска</kwd><kwd>сердечная недостаточность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>С-reactive protein</kwd><kwd>risk factors</kwd><kwd>heart failure</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Финансирование Исследование «Узнай свое сердце» является составной частью Международного проекта по сердечно-сосудистым заболеваниям в России (International Project on Cardiovascular Disease in Russia, https://knowyourheart. science / ), который реализуется при финансовой поддержке Wellcome Trust [Strategic Award 100217], UiT – Арктического университета Норвегии, Норвежского института общественного здравоохранения и Министерства здравоохранения Норвегии. Спонсоры проекта не принимали участие в разработке дизайна исследования, сборе и анализе данных, принятии решения о публикации и подготовке рукописи. Конфликт интересов не заявлен.</funding-statement><funding-statement xml:lang="en">Funding The Know Your Heart study is a part of the International project on cardiovascular disease in Russia, https://knowyourheart. science / ) supported by the Wellcome Trust [Strategic Award 100217], UiT The Arctic University of Norway, Norwegian Institute of Public Health, and Norwegian Ministry of Health and Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  No conflict of interest is reported.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lüscher TF. Inflammation: the new cardiovascular risk factor. European Heart Journal. 2018;39(38):3483–7. DOI: 10.1093/eurheartj/ehy607</mixed-citation><mixed-citation xml:lang="en">Lüscher TF. Inflammation: the new cardiovascular risk factor. European Heart Journal. 2018;39(38):3483–7. DOI: 10.1093/eurheartj/ehy607</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Guzik TJ, Libby P. Leaders in Cardiovascular Research: Peter Libby. Cardiovascular Research. 2019;115(6):e61–2. DOI: 10.1093/cvr/cvz069</mixed-citation><mixed-citation xml:lang="en">Guzik TJ, Libby P. Leaders in Cardiovascular Research: Peter Libby. Cardiovascular Research. 2019;115(6):e61–2. DOI: 10.1093/cvr/cvz069</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Prati F, Ruscica G, Marco V, Albertucci M. ‘Precision medicine’ and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory). European Heart Journal Supplements. 2019;21(Suppl B):B73–5. DOI: 10.1093/eurheartj/suz029</mixed-citation><mixed-citation xml:lang="en">Prati F, Ruscica G, Marco V, Albertucci M. ‘Precision medicine’ and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory). European Heart Journal Supplements. 2019;21(Suppl B):B73–5. DOI: 10.1093/eurheartj/suz029</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gatto L, Marco V, Contarini M, Prati F. Atherosclerosis to predict cardiac events: where and how to look for it. Journal of Cardiovascular Medicine. 2017;18:e154–6. DOI: 10.2459/JCM.0000000000000465</mixed-citation><mixed-citation xml:lang="en">Gatto L, Marco V, Contarini M, Prati F. Atherosclerosis to predict cardiac events: where and how to look for it. Journal of Cardiovascular Medicine. 2017;18:e154–6. DOI: 10.2459/JCM.0000000000000465</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pradhan AD. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. JAMA. 2001;286(3):327–34. DOI: 10.1001/jama.286.3.327</mixed-citation><mixed-citation xml:lang="en">Pradhan AD. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. JAMA. 2001;286(3):327–34. DOI: 10.1001/jama.286.3.327</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM. A Test in Context: high-sensitivity C-reactive protein. Journal of the American College of Cardiology. 2016;67(6):712–23. DOI: 10.1016/j.jacc.2015.11.037</mixed-citation><mixed-citation xml:lang="en">Ridker PM. A Test in Context: high-sensitivity C-reactive protein. Journal of the American College of Cardiology. 2016;67(6):712–23. DOI: 10.1016/j.jacc.2015.11.037</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. Drug Design, Development and Therapy. 2010;4:383–413. DOI: 10.2147/DDDT.S10812</mixed-citation><mixed-citation xml:lang="en">Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. Drug Design, Development and Therapy. 2010;4:383–413. DOI: 10.2147/DDDT.S10812</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BHCh et al. C-reactive protein and risk of heart failure. The Rotterdam Study. American Heart Journal. 2006;152(3):514–20. DOI: 10.1016/j.ahj.2006.02.023</mixed-citation><mixed-citation xml:lang="en">Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BHCh et al. C-reactive protein and risk of heart failure. The Rotterdam Study. American Heart Journal. 2006;152(3):514–20. DOI: 10.1016/j.ahj.2006.02.023</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019;139(10):1289–99. DOI: 10.1161/CIRCULATIONAHA.118.038010</mixed-citation><mixed-citation xml:lang="en">Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019;139(10):1289–99. DOI: 10.1161/CIRCULATIONAHA.118.038010</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Andreadou I, Cabrera-Fuentes HA, Devaux Y, Frangogiannis NG, Frantz S, Guzik T et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovascular Research. 2019;115(7):1117–30. DOI: 10.1093/cvr/cvz050</mixed-citation><mixed-citation xml:lang="en">Andreadou I, Cabrera-Fuentes HA, Devaux Y, Frangogiannis NG, Frantz S, Guzik T et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovascular Research. 2019;115(7):1117–30. DOI: 10.1093/cvr/cvz050</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kwak B, Ferdinandy P, Hausenloy DJ. Realizing the therapeutic potential of novel cardioprotective therapies: The EU-CARDIOPROTECTION COST Action – CA16225. Conditioning Medicine. 2018;1(3):116–23. [Av. at: https://archive-ouverte.unige.ch/unige:107091]</mixed-citation><mixed-citation xml:lang="en">Kwak B, Ferdinandy P, Hausenloy DJ. Realizing the therapeutic potential of novel cardioprotective therapies: The EU-CARDIOPROTECTION COST Action – CA16225. Conditioning Medicine. 2018;1(3):116–23. [Av. at: https://archive-ouverte.unige.ch/unige:107091]</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lefer DJ, Bolli R. Development of an NIH Consortium for PreclinicAl AssESsment of CARdioprotective Therapies (CAESAR): A Paradigm Shift in Studies of Infarct Size Limitation. Journal of Cardiovascular Pharmacology and Therapeutics. 2011;16(3–4):332–9. DOI: 10.1177/1074248411414155</mixed-citation><mixed-citation xml:lang="en">Lefer DJ, Bolli R. Development of an NIH Consortium for PreclinicAl AssESsment of CARdioprotective Therapies (CAESAR): A Paradigm Shift in Studies of Infarct Size Limitation. Journal of Cardiovascular Pharmacology and Therapeutics. 2011;16(3–4):332–9. DOI: 10.1177/1074248411414155</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jones SP, Tang X-L, Guo Y, Steenbergen C, Lefer DJ, Kukreja RC et al. The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR): A New Paradigm for Rigorous, Accurate, and Reproducible Evaluation of Putative Infarct-Sparing Interventions in Mice, Rabbits, and Pigs. Circulation Research. 2015;116(4):572– 86. DOI: 10.1161/CIRCRESAHA.116.305462</mixed-citation><mixed-citation xml:lang="en">Jones SP, Tang X-L, Guo Y, Steenbergen C, Lefer DJ, Kukreja RC et al. The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR): A New Paradigm for Rigorous, Accurate, and Reproducible Evaluation of Putative Infarct-Sparing Interventions in Mice, Rabbits, and Pigs. Circulation Research. 2015;116(4):572– 86. DOI: 10.1161/CIRCRESAHA.116.305462</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DStJ, Haffner SM et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414–9. DOI: 10.1161/01.CIR.0000080897.52664.94</mixed-citation><mixed-citation xml:lang="en">Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DStJ, Haffner SM et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414–9. DOI: 10.1161/01.CIR.0000080897.52664.94</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow RO. The role of metabolic syndrome in heart failure. European Heart Journal. 2015;36(39):2630–4. DOI: 10.1093/eurheartj/ehv350</mixed-citation><mixed-citation xml:lang="en">Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow RO. The role of metabolic syndrome in heart failure. European Heart Journal. 2015;36(39):2630–4. DOI: 10.1093/eurheartj/ehv350</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cook S, Malyutina S, Kudryavtsev AV, Averina M, Bobrova N, Boytsov S et al. Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. Wellcome Open Research. 2018;3:67. DOI: 10.12688/wellcomeopenres.14619.2</mixed-citation><mixed-citation xml:lang="en">Cook S, Malyutina S, Kudryavtsev AV, Averina M, Bobrova N, Boytsov S et al. Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. Wellcome Open Research. 2018;3:67. DOI: 10.12688/wellcomeopenres.14619.2</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal – Cardiovascular Imaging. 2015;16(3):233–71. DOI: 10.1093/ehjci/jev014</mixed-citation><mixed-citation xml:lang="en">Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal – Cardiovascular Imaging. 2015;16(3):233–71. DOI: 10.1093/ehjci/jev014</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2016;29(4):277– 314. DOI: 10.1016/j.echo.2016.01.011</mixed-citation><mixed-citation xml:lang="en">Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2016;29(4):277– 314. DOI: 10.1016/j.echo.2016.01.011</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. New England Journal of Medicine. 1997;336(14):973–9. DOI: 10.1056/NEJM199704033361401</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. New England Journal of Medicine. 1997;336(14):973–9. DOI: 10.1056/NEJM199704033361401</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GDO et al. C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51(5):1596–600. DOI: 10.2337/diabetes.51.5.1596</mixed-citation><mixed-citation xml:lang="en">Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GDO et al. C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51(5):1596–600. DOI: 10.2337/diabetes.51.5.1596</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM. Inflammatory Biomarkers, Statins, and the Risk of Stroke: Cracking a Clinical Conundrum. Circulation. 2002;105(22):2583–5. DOI: 10.1161/01.CIR.0000017822.82512.62</mixed-citation><mixed-citation xml:lang="en">Ridker PM. Inflammatory Biomarkers, Statins, and the Risk of Stroke: Cracking a Clinical Conundrum. Circulation. 2002;105(22):2583–5. DOI: 10.1161/01.CIR.0000017822.82512.62</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. The Lancet. 2001;358(9286):946–8. DOI: 10.1016/ S0140-6736(01)06112-8</mixed-citation><mixed-citation xml:lang="en">Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. The Lancet. 2001;358(9286):946–8. DOI: 10.1016/ S0140-6736(01)06112-8</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Festa A, D’Agostino R, Tracy RP, Haffner SM. Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51(4):1131–7. DOI: 10.2337/diabetes.51.4.1131</mixed-citation><mixed-citation xml:lang="en">Festa A, D’Agostino R, Tracy RP, Haffner SM. Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51(4):1131–7. DOI: 10.2337/diabetes.51.4.1131</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25. DOI: 10.1038/nature10146</mixed-citation><mixed-citation xml:lang="en">Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25. DOI: 10.1038/nature10146</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Taglieri N, Koenig W, Kaski JC. Cystatin C and Cardiovascular Risk. Clinical Chemistry. 2009;55(11):1932–43. DOI: 10.1373/clinchem.2009.128397</mixed-citation><mixed-citation xml:lang="en">Taglieri N, Koenig W, Kaski JC. Cystatin C and Cardiovascular Risk. Clinical Chemistry. 2009;55(11):1932–43. DOI: 10.1373/clinchem.2009.128397</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International. 2004;65(4):1416–21. DOI: 10.1111/j.1523-1755.2004.00517.x</mixed-citation><mixed-citation xml:lang="en">Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International. 2004;65(4):1416–21. DOI: 10.1111/j.1523-1755.2004.00517.x</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney International. 2009;75(6):652–60. DOI: 10.1038/ki.2008.638</mixed-citation><mixed-citation xml:lang="en">Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney International. 2009;75(6):652–60. DOI: 10.1038/ki.2008.638</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R et al. GFR Estimation Using Cystatin C Is Not Independent of Body Composition. American Journal of Kidney Diseases. 2006;48(5):712–9. DOI: 10.1053/j.ajkd.2006.07.001</mixed-citation><mixed-citation xml:lang="en">Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R et al. GFR Estimation Using Cystatin C Is Not Independent of Body Composition. American Journal of Kidney Diseases. 2006;48(5):712–9. DOI: 10.1053/j.ajkd.2006.07.001</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Aimo A, Januzzi JL, Vergaro G, Ripoli A, Latini R, Masson S et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation. 2018;137(3):286–97. DOI: 10.1161/CIRCULATIONAHA.117.031560</mixed-citation><mixed-citation xml:lang="en">Aimo A, Januzzi JL, Vergaro G, Ripoli A, Latini R, Masson S et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation. 2018;137(3):286–97. DOI: 10.1161/CIRCULATIONAHA.117.031560</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O’Connor CM et al. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure: Biomarkers in patients with diabetes and heart failure. European Journal of Heart Failure. 2017;19(10):1310–20. DOI: 10.1002/ejhf.912</mixed-citation><mixed-citation xml:lang="en">Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O’Connor CM et al. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure: Biomarkers in patients with diabetes and heart failure. European Journal of Heart Failure. 2017;19(10):1310–20. DOI: 10.1002/ejhf.912</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dinatolo E, Sciatti E, Anker MS, Lombardi C, Dasseni N, Metra M. Updates in heart failure: what last year brought to us. ESC Heart Failure. 2018;5(6):989–1007. DOI: 10.1002/ehf2.12385</mixed-citation><mixed-citation xml:lang="en">Dinatolo E, Sciatti E, Anker MS, Lombardi C, Dasseni N, Metra M. Updates in heart failure: what last year brought to us. ESC Heart Failure. 2018;5(6):989–1007. DOI: 10.1002/ehf2.12385</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Миролюбова О.А., Мосеева А.С., Антонов А.Б. Взаимосвязи биомаркеров и показателей эхокардиографии у больных сердечной недостаточностью с сохраненной и умеренно сниженной фракцией выброса. VI Международный образовательный форум «Российские дни сердца». 2018;43. Доступно на: https://scardio.ru/content/activities/2018/RCD/event_11984_thesises.pdf</mixed-citation><mixed-citation xml:lang="en">Mirolubova O.A., Moiseeva A.S., Antonov A.B. Relationships between biomarkers and echocardiography indicators in patients with heart failure with a preserved and moderately reduced ejection fraction. VI global educational forum “Russian cardiovascular days”. 2018;43. Av. at: https://scardio.ru/content/activities/2018/RCD/event_11984_thesises.pdf.2018.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Шадрина А.С., Плиева А.З., Кушлинский Д.Н., Морозов А.А., Филипенко М.Л., Чанг В.Л. и др. Классификация, регуляция активности, генетический полиморфизм матриксных металлопротеиназ в норме и при патологии. Альманах клинической медицины. 2017;45(4):266–79. DOI: 10.18786/2072-0505-2017-45-4-266-279</mixed-citation><mixed-citation xml:lang="en">Shadrina A.S., Plieva Ya.Z., Kushlinskiy D.N., Morozov A.A., Filipenko M.L., Chang V.L. et al. Classification, regulation of activity, and genetic polymorphism of matrix metalloproteinases in health and disease. Almanac of Clinical Medicine. 2017;45(4):266–79. DOI: 10.18786/2072-0505-2017-45-4-266-279</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
